Search Medical Condition
Please enter condition
Please choose location

Sankt Augustin, Germany Clinical Trials

A listing of Sankt Augustin, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (93) clinical trials

Study to Evaluate the Efficacy and Safety of REGN2222 for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

This study occurs in two parts: Part A and Part B. The status of Part A is 'Complete'. The status of Part B is 'Recruiting.' Part A of the study is an open-label, PK evaluation of intramuscular (IM) administered REGN2222 in preterm infants for whom palivizumab is not recommended to ...

Phase

0.0 miles

Learn More »

Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age

The purpose of this study is 1. to monitor short children born SGA who were treated with growth hormone in study EP00-401 for the development of diabetes for a further 10 years after termination of growth hormone treatment and 2. to report the incidence of anti-rhGH antibodies and of E. ...

Phase N/A

0.0 miles

Learn More »

-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

This two-part open-label study will assess 2 different canakinumab taper regimens in patients with clinical remission (inactive disease for at least 24 continuous weeks) on canakinumab treatment without concomitant corticosteroids (CS) or methotrexate (MTX). The study will also collect long term safety and tolerability data on SJIA patients treated with ...

Phase

0.94 miles

Learn More »

An Open-label Ascending Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

The total study duration per patient will be 114 weeks that will consist of a 4-week screening, a 12-week core treatment period, a 92-week extension phase, and a 6-week post-treatment follow-up.

Phase

0.94 miles

Learn More »

Efficacy Pharmacokinetics Safety and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

This is a prospective, multi-center, open-label, single-arm, efficacy, PK, safety and tolerability study of IGSC 20% in subjects with PI. Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated with subcutaneously administered IGSC 20% who complete the entire study. This ...

Phase

0.94 miles

Learn More »